10x Genomics, Inc.
TXGNASDAQHealthcare● Active
$29.37
$-1.68(-5.40%)
Market Cap$3.7B
P/E Ratio—
52W High$32.31
52W Low$8.945
10x Genomics, Inc. (TXG) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
TXG · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.10
Est. -$0.29 · +65.5%
Revenue
$0.15B
Est. $0.15B · +3.0%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 2-Quarter EPS Beat Streak
TXG reports quarterly as a NASDAQ-listed Medical - Healthcare Information Services company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.37
Rev. $0.36B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.37
Rev. Est.$0.36B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.23 | — | — | — | $0.15B | — |
| ▲ Q2 FY2026 | May 7, 2026 | -$0.29 | -$0.10 | +65.5% | $0.15B | $0.15B | +3.0% |
| ▲ Q1 FY2026 | Feb 12, 2026 | -$0.19 | -$0.13 | +31.6% | $0.17B | $0.16B | +4.0% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -$0.07 | -$0.22 | -214.3% | $0.15B | $0.14B | +4.6% |
| ▲ Q3 FY2025 | Aug 7, 2025 | -$0.35 | $0.28 | +180.0% | $0.17B | $0.14B | +23.9% |
| ▲ Q2 FY2025 | May 8, 2025 | -$0.45 | -$0.36 | +20.0% | $0.15B | $0.15B | +6.6% |
| ▼ Q1 FY2025 | Feb 12, 2025 | -$0.29 | -$0.40 | -37.9% | $0.17B | $0.16B | +0.0% |
| ▲ Q4 FY2024 | Oct 29, 2024 | -$0.34 | -$0.30 | +11.8% | $0.15B | $0.15B | -1.1% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.23
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
-$0.10
EPS Est.
-$0.29
EPS Surpr.
+65.5%
Revenue
$0.15B
Q1 FY2026
Feb 12, 2026Beat
EPS Actual
-$0.13
EPS Est.
-$0.19
EPS Surpr.
+31.6%
Revenue
$0.17B
Q4 FY2025
Nov 6, 2025Miss
EPS Actual
-$0.22
EPS Est.
-$0.07
EPS Surpr.
-214.3%
Revenue
$0.15B
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
$0.28
EPS Est.
-$0.35
EPS Surpr.
+180.0%
Revenue
$0.17B
Q2 FY2025
May 8, 2025Beat
EPS Actual
-$0.36
EPS Est.
-$0.45
EPS Surpr.
+20.0%
Revenue
$0.15B
Q1 FY2025
Feb 12, 2025Miss
EPS Actual
-$0.40
EPS Est.
-$0.29
EPS Surpr.
-37.9%
Revenue
$0.17B
Q4 FY2024
Oct 29, 2024Beat
EPS Actual
-$0.30
EPS Est.
-$0.34
EPS Surpr.
+11.8%
Revenue
$0.15B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.10 | $-0.10 | $-0.10 | 3 |
| Q3 FY2028 | $-0.17 | $-0.17 | $-0.17 | 2 |
| Q2 FY2028 | $-0.19 | $-0.19 | $-0.19 | 2 |
| Q1 FY2028 | $-0.04 | $-0.04 | $-0.04 | 3 |
| Q4 FY2027 | $-0.12 | $-0.12 | $-0.11 | 2 |
| Q3 FY2027 | $-0.16 | $-0.16 | $-0.16 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.2B | $0.2B | $0.2B | 4 |
| Q3 FY2028 | $0.2B | $0.2B | $0.2B | 4 |
| Q2 FY2028 | $0.2B | $0.2B | $0.2B | 4 |
| Q1 FY2028 | $0.2B | $0.2B | $0.2B | 4 |
| Q4 FY2027 | $0.2B | $0.2B | $0.2B | 5 |
| Q3 FY2027 | $0.2B | $0.2B | $0.2B | 5 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +65.5% | $22.74 | $22.42 | -1.41% |
| ▲ Q1 FY2026 | Feb 12, 2026 | +31.6% | $19.15 | $17.51 | -8.56% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -214.3% | $13.49 | $13.00 | -3.63% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +180.0% | $12.66 | $12.80 | +1.11% |
| ▲ Q2 FY2025 | May 8, 2025 | +20.0% | $8.31 | $8.63 | +3.85% |
| ▼ Q1 FY2025 | Feb 12, 2025 | -37.9% | $11.82 | $12.00 | +1.52% |
| ▲ Q4 FY2024 | Oct 29, 2024 | +11.8% | $15.86 | $15.79 | -0.44% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +31.9% | $18.13 | $19.55 | +7.83% |
Q2 FY2026-1.41%
Report Date
May 7, 2026
EPS Beat/Miss
+65.5%
Price Before
$22.74
Price After
$22.42
Q1 FY2026-8.56%
Report Date
Feb 12, 2026
EPS Beat/Miss
+31.6%
Price Before
$19.15
Price After
$17.51
Q4 FY2025-3.63%
Report Date
Nov 6, 2025
EPS Beat/Miss
-214.3%
Price Before
$13.49
Price After
$13.00
Q3 FY2025+1.11%
Report Date
Aug 7, 2025
EPS Beat/Miss
+180.0%
Price Before
$12.66
Price After
$12.80
Q2 FY2025+3.85%
Report Date
May 8, 2025
EPS Beat/Miss
+20.0%
Price Before
$8.31
Price After
$8.63
Q1 FY2025+1.52%
Report Date
Feb 12, 2025
EPS Beat/Miss
-37.9%
Price Before
$11.82
Price After
$12.00
Q4 FY2024-0.44%
Report Date
Oct 29, 2024
EPS Beat/Miss
+11.8%
Price Before
$15.86
Price After
$15.79
Q3 FY2024+7.83%
Report Date
Aug 8, 2024
EPS Beat/Miss
+31.9%
Price Before
$18.13
Price After
$19.55
Avg Beat Reaction+0.40%
Avg Miss Reaction-1.05%
Beat Rate6 / 8 quarters
Largest Move-8.56% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: TXG ends December
10x Genomics, Inc. (TXG) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.10 — beating the analyst consensus of $-0.29 by +65.5%. TXG has beaten EPS estimates for 2 consecutive quarters. The next TXG earnings date is expected around September 1, 2026.
Each quarter, investors track TXG earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. TXG revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
TXG's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
TXG earnings · 5 questions10x Genomics, Inc.'s next earnings report is expected around September 1, 2026. TXG typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; TXG historically reports after market close (AMC).
TXG earnings datewhen is TXG earningsTXG next earnings datewhen does TXG report earningsTXG earnings calendar
▸ Source: FMP · 10x Genomics, Inc. SEC filings · US GAAP · 10x Genomics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026